Fotosearch_k18326703_spegelvänd.jpg

SWIPP

About us

Board and Management

OWNERS

Christer Sjögren   is Doctor in Veterinary Medicine (DVM), PhD, and Associate Professor in Pharmacology at the Swedish Royal Veterinary College in 1975, as well as former Consulting Professor in experimental Obstetrics and Gynecology at Uppsala University in Sweden.  He has more than 45 years of experience from leading positions at big pharmaceutical companies such as Pharmacia and Novo Nordisk as well as smaller such as Perstorp Pharma, LIDDS AB, Peptonic Medical AB and others.
Christer Sjögren   is Doctor in Veterinary Medicine (DVM), PhD, and Associate Professor in Pharmacology at the Swedish Royal Veterinary College in 1975, as well as former Consulting Professor in experimental Obstetrics and Gynecology at Uppsala University in Sweden.  He has more than 45 years of experience from leading positions at big pharmaceutical companies such as Pharmacia and Novo Nordisk as well as smaller such as Perstorp Pharma, LIDDS AB, Peptonic Medical AB and others.

Christer Sjögren
is Doctor in Veterinary Medicine (DVM), PhD, and Associate Professor in Pharmacology at the Swedish Royal Veterinary College in 1975, as well as former Consulting Professor in experimental Obstetrics and Gynecology at Uppsala University in Sweden.

He has more than 45 years of experience from leading positions at big pharmaceutical companies such as Pharmacia and Novo Nordisk as well as smaller such as Perstorp Pharma, LIDDS AB, Peptonic Medical AB and others.

Bengt Westrin  has over 26 years industry experience,  spanning from startups to big pharma, from product  development & regulatory affairs to project management  & business development.  Prior to SWIPP he has been CEO of CombiGene AB (publ),  AcuCort AB (publ), Idogen AB (publ), Lipopeptide AB (Stockholm),  and VP Business Development of Camurus AB(publ).  He has also had numerous consultancy assignment for other public  or private companies.  He received his M.Sc. and his Ph.D. at the Faculty of Engineering at Lund University, where he is also Associate Professor since 1999.
Bengt Westrin   has over 26 years industry experience,  spanning from startups to big pharma, from product  development & regulatory affairs to project management  & business development.  Prior to SWIPP he has been CEO of CombiGene AB (publ),  AcuCort AB (publ), Idogen AB (publ), Lipopeptide AB (Stockholm),  and VP Business Development of Camurus AB (publ).  He has also had numerous consultancy assignment for other public  or private companies.  He received his M.Sc. and his Ph.D. at the Faculty of Engineering at Lund University, where he is also Associate Professor since 1999.

Bengt Westrin
has over 26 years industry experience,
spanning from startups to big pharma, from product
development & regulatory affairs to project management
& business development.

Prior to SWIPP he has been CEO of CombiGene AB (publ),
AcuCort AB (publ), Idogen AB (publ), Lipopeptide AB (Stockholm),
and VP Business Development of Camurus AB (publ).

He has also had numerous consultancy assignment for other public
or private companies.

He received his M.Sc. and his Ph.D. at the Faculty of Engineering at Lund University, where he is also Associate Professor since 1999.

Johan Säfholm, M.Sc. Board member
Johan Säfholm   got his Masters degree in Applied Physics from Linköping University in 2003.  He has since gained international experience from development and manufacturing of consumer electronics in different roles such as team leader and product manager.  Johan has worked at Sony Ericsson, ST-Ericsson, Axis and Flatfrog, companies spanning from 40 to 5000 employees with worldwide presence.

Johan Säfholm
got his Masters degree in Applied Physics from Linköping University in 2003.

He has since gained international experience from development and manufacturing of consumer electronics in different roles such as team leader and product manager.

Johan has worked at Sony Ericsson, ST-Ericsson, Axis and Flatfrog, companies spanning from 40 to 5000 employees with worldwide presence.

Bruno Loiseaumed text.png
After four years in strategy consulting (AT Kearney), Bruno Loiseau joined the Burgundy Ventures Group in 2005 and co-founded AdhexPharma for the purpose of acquiring the patch unit of Solvay Pharmaceutical. Since that time, AdhexPharma has grown over 30% per year, registering 4 new drug products as a CDMO and is currently developing several oral thin films and patches. Bruno Loiseau has an MBA from ESSEC Business School, and is a French citizen.

After four years in strategy consulting (AT Kearney), Bruno Loiseau joined the Burgundy Ventures Group in 2005 and co-founded AdhexPharma for the purpose of acquiring the patch unit of Solvay Pharmaceutical. Since that time, AdhexPharma has grown over 30% per year, registering 4 new drug products as a CDMO and is currently developing several oral thin films and patches. Bruno Loiseau has an MBA from ESSEC Business School, and is a French citizen.

SWIPP is currently owned by the two
co-founders Christer Sjögren and Bengt Westrin, together with three Swedish seed investors and AdhexPharma (France).